I Was Told That What House Dems Are Mulling Against Trump Was an...
Why a Catholic Bishop Said This MSNBC Segment Was One of the Most...
After Two Centuries, Remington Will Soon Be Out of New York
Red State Governors Compete to Cut Taxes, Blue States Fall Further Behind
Hey, Biden! Brennan! Wanna See Some GENUINE Russian Colluders? Look in the Mirror
If Non Citizens May Vote, What Is the Point of Being a U.S....
Suspect Charged With Killing Georgia Student Is An Illegal Migrant From Venezuela
'Grid Down, Power Up:' Dennis Quaid Warns About What the U.S. Is Not...
Biden Associate James Galanis: Hunter's Value 'Was His Family Name and His Access...
The Problem With Pride
Why Did the Threat of an EMP From Space Throw DC Into a...
The Border and the Debt
Don’t Want to Pay for Health Care or Groceries? Then Don’t. Pretend to...
How China Went From Famine to Economic Miracle
Despite Biden Admin Promises of Keeping New Drug Prices Down, Big Pharma Sees...
Tipsheet

Pfizer Is Testing an Oral Drug to Fight COVID-19

AP Photo/Paul Sancya

Pharmaceutical corporation Pfizer is in mid-to-late stage trials to test an oral drug designed to fight the Wuhan coronavirus, the company announced Monday.

In a statement released by Pfizer, the company announced antiviral candidate PF-07321332, the drug that would be used to treat the virus. “Results from the Phase 1 clinical trial demonstrated that PF-07321332 was safe and well tolerated,” the announcement reads. Currently, the company is in Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis), which is being tested on adults 18 and older who live in a household with another person with a confirmed COVID-19 case.

Advertisement

“With the continued impact of COVID-19 around the world, we believe that tackling the virus will require effective treatments for people who contract, or have been exposed to, the virus, complementing the impact that vaccines have had in helping quell infections,” Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer said in a statement. “If successful, we believe this therapy could help stop the virus early – before it has had a chance to replicate extensively – potentially preventing symptomatic disease in those who have been exposed and inhibiting the onset of infection in others.”

According to the news release, PF-07321332 is designed to be administered orally and meant to be prescribed at the first sign of infection. It is a “protease inhibitor,” designed to block the activity of the main protease enzyme that COVID-19 needs to replicate. If the drug is co-administered with a low dose of the drug ritonavir, it is expected to slow the metabolism of PF-07321332 in order for it to stay active in the body for longer periods of time at higher concentrations to fight the virus.

“Given the continued emergence and evolution of SARS-CoV-2 variants and their immense impact, we continue to work diligently to develop and study new ways that our investigational oral antiviral candidate could potentially lower the impact of COVID-19, not only on patients’ lives, but also the lives of their families and household members,” Dolsten said in a statement.

Advertisement

Today, Pfizer reportedly submitted data regarding their COVID-19 vaccine to the Food and Drug Administration’s (FDA) to attain Emergency Use Authorization (EUA) for the vaccine for children ages 5 to 11. As of right now, Pfizer is the only COVID-19 vaccine that has received the FDA’s full and final approval for eligible adults.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement